,trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca
['trastuzumab', 'lung', 'bcsm', 'breast']
on the destiny breast rial and risk of ild with trastuzumab deruxtecan .. cannot overemphasize the importance of oncologist review of ct chest lung window and not rely on report alone (which frequently underestimates/underreports ild). #bcsm #onctwitter #asco22 1/2
Medical oncologist - Developmental Therapeutics - NIH/NCI - opinions my own - retweet ? endorsement - will summarize oncology news in one tweet each